TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

1.1121 Vincent JL. Drotrecogin alfa (activated) in the treatment of severe sepsis. Expert Rev Anti Infect Ther 2006;4:537-47. 1.1122 Kreymann KG et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85. 1.1123 Laupland KB et al. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35: 2686-92. 1.1124 Werdan K et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007;35:2693-701. 1.1125 Soylemez Wiener R et al. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. J Am Med Assoc 2008;300:933-44. 1.1126 Finfer S et al. Tight glycemic control in critically ill adults. J Am Med Assoc 2008;300:963-5. 1.1127 COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock in adults. A randomized controlled trial. J Am Med Assoc 2010;303:341-8. 1.1128 Brunkhorst FM et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39. 1.1129 NICE-SUGAR investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97. 1.1130 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327. 1.1131 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60. 1.1132 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:783-85. 1.1133 O‘Grady NO et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008;36:1330-49. 1.1134 Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-713. 1.1135 Mackenzie I et al. Management of sepsis. Br Med J 2007;335:929-32. 1.1136 O‘Brien JM et al. Sepsis. Am J Med 2007;120:1012-22. 1.1137 Annane D et al. Septic shock. Lancet 2005;365:63-78. 1.1138 Sharma VK et al. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther 2006;4:395-403. 1.1139 Hotchkiss RS et al. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50. 1.1140 Talan DA et al. Severe sepsis and septic shock in the emergency department. Infect Dis Clin North Am 2008;22:1-31. 1.1141 Venkatesh MP et al. Management of neonatal sepsis by Gram-negative pathogens. Expert Rev Anti Infect Ther 2008;6:929-38. 1.1142 Schrag SJ et al. Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis. Pediatr Infect Dis J 2006;25:939-40. 1.1143 Hart AC et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90. 1.1144 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196-210. 1.1145 Hart AC et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90. 1.1146 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196-210. 1.1147 Cunha BA. Fever of unknown origin: clinical overview of classic and current concepts. Infect Dis Clin North Am 2007;21:867-915. 1.1148 Knockaert DC. Recurrent fevers of unknown origin. Infect Dis Clin North Am 2007;21:1189-211. 1.1149 Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. 1.1150 Marti Marti F et al. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 2009;20(suppl. 4):iv166-69. 1.1151 Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. 1.1152 Cometta A et al. Empirical use of anti-Gram-positive antibiotics in febrile neutropenic cancer patients with acute leukaemia. Eur J Cancer Suppl 2007;5:23-31. 1.1153 Antoniadou A et al. Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 2007;21: 1055-90. 1.1154 Aoun M. Empiric therapy for febrile neutropenia: what are the choices? Expert Rev Anti Infect Ther 2007;5:507-15. 1.1155 Castagnola E et al. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation. Expert Rev Anti Infect Ther 2009;7:607-21. 1.1156 Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009;101 (suppl. 1):S18-22. 1.1157 Meckler G et al. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am 2009;27:525-44. 1.1158 Ellis M. Febrile neutropenia. Ann NY Acad Sci 2008;1138:329-350. 1.1159 Attygalle D et al. New trends in the management of tetanus. Expert Rev Anti Infect Ther 2004;2:73- 84. 1.1160 Brook I. Current concepts in the management of Clostridum tetani infection. Expert Rev Anti Infect Ther 2008;6:327-36. 1.1161 Ahmadsyah I et al. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J 1985;291:648-50. 1.1162 Kabura L et al. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health 2006;11: 1075-81. 1.1163 Lappin E et al. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-90. 1.1164 Fischer M et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005;353:2352-60. 1.1165 Sinave C et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002;35:1441-3.
1.1166 Aldape MJ et al. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006;43:1436-46. 1.1167 Fjerstad M et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009;361:145-51. 1.1168 Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. J Am Med Assoc 1993;269:390-1. 1.1169 Shah SS et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009;49:1369-76. 1.1170 Schrage B et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006;43:743-6. 1.1171 Stevens DL. The flesh-eating bacterium: what‘s next? J Infect Dis 1999;179(suppl. 2):S366-74. 1.1172 Sendi P et al. Bacterial phenotype variants in group b streptococcal toxic shock syndrome. Emerg Infect Dis 2009;15:223-32. 1.1173 Stevens DL et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-11. 1.1174 Crump JA et al. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010;50:241-6. 1.1175 Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. Br Med J 2006;333:78- 82. 1.1176 Bhan MK et al. Typhoid and paratyphoid fever. Lancet 2005;366:749-62. 1.1177 Connor BA et al. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5;623-8. 1.1178 Huang DB et al. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis 2005;5:341-8. 1.1179 Thaver D et al. A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: a meta-analysis. Br Med J 2009;338:b1865. 1.1180 Lynch MF et al. Typhoid fever in the United States, 1999-2006. J Am Med Assoc 2009;302:859-65. 1.1181 Frenck RW et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004;38:951-7. 1.1182 Hoffman SL et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984;310:82-8. 1.1183 Raad I et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis 2009;49:1187-94. 1.1184 Casey AL et al. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis 2008;8:763-76. 1.1185 Rijnders BJ et al. Watchful waiting versus immediate catheter removal in UCI patients with suspected catheter-related infection: a randomized trial. Intensive Care Med 2004:30:1073-80. 1.1186 Worthington T et al. Diagnosis of central venous catheter related infection in adult patients. J Infect 2005;51:267-80. 1.1187 Bouza E et al. A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. Clin Infect Dis 2007;44:820-6. 1.1188 Mermel LA et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45. 1.1189 Perlman SE at al. Risk factors for late-onset healthcare-associated bloodstream infections in patients in neonatal intensive care units. Am J Infect Control 2007;35:177-82. 1.1190 Raad I et al. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007;7:645-57. 1.1191 Pagani JL et al. Management of catheter-related infection. Expert Rev Anti Infect Ther 2008;6:31-7. 1.1192 Parienti JJ et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy. A randomized controlled trial. J Am Med Assoc 2008;299: 2413-22. 1.1193 Lorente L et al. Arterial catheter-related infection of 2,949 catheters. Crit Care 2006;10:R83. 1.1194 McBryde ES et al. Comparison of contamination rates of catheter-drawn and peripheral blood cultures. J Hosp Infect 2005;60:118-21. 1.1195 Raad I et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004;140:18-25. 1.1196 Yahav D et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 2008;47:83-93. 1.1197 Rijnders BJ et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005;55:90-4. 1.1198 Garland JS et al. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infections in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. Pediatrics 2005;116:e198-205. 1.1199 Toltzis P. Antibiotic lock technique to reduce central venous catheter-related bacteremia. Pediatr Infect Dis J 2006;25:449-50. 1.1200 Korbila IP et al. Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence. Expert Rev Anti Infect Ther 2007;5:639-52. 1.1201 Safdar N et al. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infections associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006;43:474-84. 1.1202 Falagas ME et al. Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review. Eur J Pharmacol 2007;557:93-8. 1.1203 Volkow P et al. Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials. Thromb J 2005;3:11. 1.1204 Mertz D et al. Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users. Clin Infect Dis 2008;46:741-4. 1.1205 Faro C et al. Postoperative pelvic infections. Infect Dis Clin North Am 2008;22:653-63. 1.1206 Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008;27:1-7. 1.1207 Grundmann H et al. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med 2010;7:e1000215. 1.1208 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of oppor-
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25: of severe respiratory failure. Clin
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78:
tients. J Antimicrob Chemother 2009
Page 79 and 80:
duct characteristics. Available at:
Page 81 and 82:
_Product_Information/human/000338/W
Page 83 and 84:
114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86:
North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88:
1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90:
21.358 Calabrese LH et al. Viral Ar
Page 91 and 92:
24. 21.452 Jeha LE et al. Long term
Page 93 and 94:
induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?